TAK-733   Click here for help

GtoPdb Ligand ID: 9911

Synonyms: compound 17 [PMID: 21310613] | example 18 [US8470837] | TAK733
PDB Ligand
Compound class: Synthetic organic
Comment: TAK-733 is a potent and selective MEK inhibitor with an allosteric binding mode, that was designed as a novel cancer chemotherapeutic [3].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 3
Rotatable bonds 5
Topological polar surface area 109.38
Molecular weight 504.01
XLogP 2.69
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES OCC(Cn1cnc2c(c1=O)c(Nc1ccc(cc1F)I)c(c(=O)n2C)F)O
Isomeric SMILES OC[C@@H](Cn1cnc2c(c1=O)c(Nc1ccc(cc1F)I)c(c(=O)n2C)F)O
InChI InChI=1S/C17H15F2IN4O4/c1-23-15-12(16(27)24(7-21-15)5-9(26)6-25)14(13(19)17(23)28)22-11-3-2-8(20)4-10(11)18/h2-4,7,9,22,25-26H,5-6H2,1H3/t9-/m1/s1
1. Adjei AA, LoRusso P, Ribas A, Sosman JA, Pavlick A, Dy GK, Zhou X, Gangolli E, Kneissl M, Faucette S et al.. (2017)
A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors.
Invest New Drugs, 35 (1): 47-58. [PMID:27650277]
2. Akinleye A, Furqan M, Mukhi N, Ravella P, Liu D. (2013)
MEK and the inhibitors: from bench to bedside.
J Hematol Oncol, 6: 27. [PMID:23587417]
3. Dong Q, Dougan DR, Gong X, Halkowycz P, Jin B, Kanouni T, O'Connell SM, Scorah N, Shi L, Wallace MB et al.. (2011)
Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer.
Bioorg Med Chem Lett, 21 (5): 1315-9. [PMID:21310613]